Articles related to COMBINATION THERAPY

The American Academy of Sleep Medicine just clarified where combination therapy fits for chronic insomnia. Spoiler: CBT-I still wins, but pharmacotherapy alone has a narrower role.

In two randomized phase‑3 trials, a single‑pill triple low‑dose antihypertensive combination achieved blood pressure reductions comparable to amlodipine and superior to losartan monotherapy over 8 weeks.

Treatment options for platinum‑resistant ovarian cancer remain limited. New phase 3 survival data suggest that adding a novel agent to standard chemotherapy may meaningfully extend survival for this hard‑to‑treat population.

As GLP‑1 medications become widely used for obesity and metabolic disease, clinicians are confronting a growing question: What should be done when patients don’t respond as expected?

The combined action of the drugs results in pupil constriction, resulting in a pinhole effect that improves near visual acuity and depth of focus in patients with presbyopia.

“Patients treated in the Optune Pax arm had a median time to pain progression of 15.2 months compared to 9.1 months.” — PANOVA-3 Trial, FDA Approval Announcement